

FSD Pharma

14:07 24 Apr 2019

FSD Pharma to exchange shares with Aura Health

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) announced Wednesday that it has entered into a share exchange transaction with Toronto-based cannabis firm Aura Health Inc (OTCMKTS:LMLLF).

Specifically, Ontario-based FSD Pharma will exchange 13,181,019 of its common shares for 13,562,386 Aura shares valued at C\$3 million.

Aura Health is a Toronto-based cannabis company building an international network of vertically integrated businesses in the medical cannabis industry.

READ: FSD Pharma to acquire US specialty R&D pharma company Prismic Pharmaceuticals for US\$17.5M in stock

A consulting agreement is part of the deal under which Aura will help FSD secure euGMP certification at its existing licensed facility through Hamburg, Germany-based Pharmadrug Production GmbH. Aura is also in the process of acquiring an 80% stake in Pharmadrug.

Cannabis supplier to Pharmadrug

FSD Pharma expects to be a preferred but not sole cannabis supplier to Pharmadrug for the German market once this happens. Pharmadrug will initially commit to buying approximately 1,000 kilograms of Canadian produced cannabis from FSD Pharma at a price of C\$7 per gram provided the product is saleable in the German market.

Zeeshan Saeed, Founder and President of FSD commented,

"This agreement with Aura Health establishes a distribution channel for FSD in Germany and the Eurozone and allows the company to expand its footprint internationally," said FSD Pharma founder and president Zeeshan Saeed. "As production at our Cobourg facility grows and following receipt of our euGMP certification, we will be able to supply our high-quality cannabis products to the medical markets in Europe."

FSD Pharma is headquartered at the former Kraft plant in Cobourg, Ontario in a large facility that sits on 72 acres of land. It grows medical-grade cannabis at its 25,000 square foot facility in Ontario, with an additional 220,000 expected to be added by the end of 2019.

The company intends to target all legal aspects of the cannabis industry: cultivation, processing, manufacturing, extracts and research and development.

"This is an exciting opportunity for FSD Pharma to capitalize in the global medicinal cannabis space. The global market is expected to grow and remain undersupplied for some time," said FSD Pharma CEO Dr Raza Bokhari. "In collaboration with Aura Health, we see an opportunity to increase shareholder value by establishing channel partners in Germany and the Eurozone."

Price: 8.29

Market Cap: \$64.8 m

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: HUGE

Listing: CSE

52 week High Low
73.365 4.4

Sector: Cannabis

Website: fsdpharma.com

Company Synopsis:

FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc. , holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

action@proactiveinvestors.com

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).